Use of nicotinic acid in patients with elevated fasting glucose, diabetes, or metabolic syndrome

British Journal of Diabetes and Vascular Disease

Volumn 4, Issue 2, 2004, Pages 78-85

  McGovern, Mark E ^a  

^a NONE   (United States)

Author keywords

Diabetes metabolic syndrome; Dyslipidaemia; IFG; Nicotinic acid

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIOXIDANT; ATORVASTATIN; CLOFIBRATE; DEXTROTHYROXINE; ESTROGEN; FIBRIC ACID DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MEVINOLIN; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; PLACEBO; PRAVASTATIN; SIMVASTATIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; TROGLITAZONE; WARFARIN;

ATHEROGENESIS; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DIABETES CONTROL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; FLUSHING; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSURIA; GOUT; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LIVER TOXICITY; MALE; METABOLIC SYNDROME X; MYALGIA; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 2442488856     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514040040020301     Document Type: Review

References (34)

1. Tavintharan S, Kashyap ML. The benefits of niacin in atherosclerosis. Curr Atheroscler Rep 2001;3:74-82.
2. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
3. Canner PL, Berge KG, Wenger NK et al. Fifteen-year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.
4. Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
5. Blankenhorn DH, Nessim SA, Johnson RL et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-40.
6. Brown BG, Zhao X-Q, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;3435:1583-92.
7. Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells: implications for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997;17:2020-8.
8. Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the key effector of reverse cholesterol transport atp-binding cassette a1 in monocytoid cells by niacin. Biochem Pharmacol 2004;67:411-19.
9. Jin FY, Kamanna VS, Kashyap ML. Niacin accelerates intracellular apob degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol 1999;19:1051-9.
10. Ganji SH, Kamanna VS, Kashyap ML. Niacin and cholesterol: role in cardiovascular disease. J Nutr Biochem 2003;6:298-305.
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002;106:3143-421.
12. International Atherosclerosis Society Harmonized Clinical Guidelines on Prevention of Atherosclerotic Vascular Disease 2003 Full Report. Available at www.athero.org
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: A Randomised Placebo-Controlled Trial. Lancet 2002;360:7-22.
14. Foot DK, Lewis RP, Pearson TA, Beller GA. Demographics and cardiology, 1950-2050. J Am Coll Cardiol 2000;35:1067-81.
15. Brown BG, Brockenbrough A, Zhao X-Q et al. Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: A 10-Year Familial Atherosclerosis Treatment Study (FATS) follow up: Circulation 1998;98:I-635.
16. Morgan JM, Capuzzi DM, Guyton JR et al. Treatment effect of niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther 1996;1:195-202.
17. Knopp RH, Alagona P, Davidson M et al. Equivalent efficacy of a time-release form of niacin (niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998;9:1097-104.
18. Goldberg A, Alagona P, Capuzzi DM et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000;85:1100-05.
19. Knopp RH. Evaluating niacin in its various forms. Am J Cardiol 2000;86: 51L-56L.
20. Davidson MH. Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol 2002;90:50K-60K.
21. Ford ES, Giles WH, Dietz WH et al. Prevalence of the metabolic syndrome amongst US adults: findings from the third national health and nutrition examination survey. JAMA 2002;287:356-9.
22. Narayan KM Venkat, Boyle JP, Thompson TJ et al. Lifetime risk for diabetes mellitus in the United States. JAMA 2003;290:1884-90.
23. Kreisberg RA. Diabetic Dyslipidemia. Am J Cardiol 1998;82:67U-73U.
24. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin dependent diabetes mellitus. JAMA 1990;264:723-6.
25. Randle PJ. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 1998;14:263-83.
26. Capuzzi DM, Morgan JM, Brusco OA, Intenzo CM. Niacin dosing: relationship to benefits and adverse events. Curr Atheroscler Rep 2000;2:64-71.
27. O'Keefe JH, Miles JM, Harris WH et al. Improving the adverse cardiovascular prognosis of type 2 diabetes. Mayo Clin Proc 1999;74:171-80.
28. Elam MB, Hunninghake DB, Davis KB et al. Effect of niacin on lipid and lipoprotein levels and glycaemic control in patients with diabetes and peripheral arterial disease. The ADMIT Study: A randomised trial. JAMA 2000;284:1263-70.
29. Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002;162:1568-76.
30. Canner PL, Furberg CD, McGovern ME. Niacin decreases myocardial infarction and total mortality in patients with impaired fasting glucose or glucose intolerance: results from the coronary drug project. Circulation 2002;106(suppl II):3138.
31. Hunninghake DB, McGovern ME, Koren M et al. A dose-ranging study of a new, once-daily dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol 2003;26:112-18.
32. Insull W, McGovern ME, Schrott H et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med 2004 (accepted for publication).
33. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
34. Canner PL, Furberg CD, Terrin ML, McGovern ME. Niacin decreases myocardial infarction and total mortality in patients with metabolic syndrome: results from the coronary drug project. J Am Coll Cardiol 2003; 41(suppl A):291A.